4CPS-094 Evaluation of adherence and virological response in patients with hepatitis B infection

<h3>Background and Importance</h3> Hepatitis B virus (HBV) is a viral infection that represents a challenge to world public health. Although antiviral treatment is effective, adherence plays a fundamental role in the disease response. <h3>Aim and Objectives</h3> The purpose of this study is to assess the adherence to treatment and the virological response (VR) in a cohort of patients with HBV infection. <h3>Material and Methods</h3> Observational, retrospective, single-centre study of a cohort of HBV patients treated with tenofovir and/or entecavir in April 2024. Patients coinfected with HIV/HBV and in which indication was prophylaxis (immunosuppression) were excluded. Adherence was estimated as the medication possession rate (MPR) in last year (least 3 months). When the medication gap was more than 90 days was considered treatment abandonment. For the analysis was used the last viral load. A VR was considered when HBV-DNA levels were &lt;10 IU/mL; partial VR when the decrease in HBV-DNA was greater than log10 but still detectable after 12 months of treatment. Demographic data, HBV-DNA viral load and treatment information were obtained from the clinical history. For statistical analysis were used percentages for categorical variables; means and standard deviations for continuous variables. <h3>Results</h3> 104 patients were included, 75% male, mean age 54 years (SD 15). 58% were treated with tenofovir; 40% entecavir and 2% with both. The time since treatment start was &lt;1 year in 6% patients, 72% between 1–10 years and 22% patients &gt;10 years. The mean adherence was 95,2% (SD 9,1). 84% of patients had adherence ≥90%, 94% patients &gt;80% and only 6 had &lt;80%. One patient abandoned treatment. There are no differences in adherence between the groups of patients treated with entecavir and tenofovir, 95,1% (SD 9,3) and 95,1% (SD 9). 99 patients (95%) presented VR; 3 partial VR and 2 patients not completed 1 year of treatment, although in all of them adherence was 99–100%. <h3>Conclusion and Relevance</h3> Patients with HBV on antiviral treatment in our study have optimal levels of adherence, indepently of the prescribed treatment. Also they have excellent VR in most cases. Is interesting to have identified patients with suboptimal adherence, especially dropouts and those with insufficient VR. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest